IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.

ABSTRACT:

Background & aims

The combination of pegylated interferon (IFN) α and ribavirin (RBV) is the standard therapy for patients with chronic HCV infection. However, it produces a sustained virologic response (SVR) in only half of the treated individuals and is associated with significant side effects. Recently, several single-nucleotide polymorphisms (SNPs) near the IL28B locus, also known as IFNλ3, were identified to be strong predictors of SVR in patients receiving PEG-IFN and RBV. We sought to determine whether IL28B was capable of inhibiting HCV replication and to determine the pathway by which IL28B exhibits anti-HCV activity.

Methods

Using the full-length HCV replicon OR6 and the infectious HCV clones JFH1 and Jc1, we assessed the anti-HCV effect of IL28B on HCV and charact

SUBMITTER: Zhang L 

PROVIDER: S-EPMC3068235 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature